Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals Crashes 50% Following 'Refusal To File' Letter From FDA

Press Releases February 17, 2016

Hearing Catalyst Pharma Defended at SunTrust

Press Releases February 17, 2016

GoPro Spikes to High on Volume

Press Releases February 17, 2016

Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse

Press Releases February 17, 2016

Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis

GlobeNewswire February 8, 2016

Catalyst Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

GlobeNewswire February 4, 2016

Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes

GlobeNewswire December 17, 2015

A Change in Tides - Analyst Notes on Hemisphere Media Group, AngioDynamics, ChemoCentryx and Catalyst Pharmaceuticals

Accesswire December 17, 2015

Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115

GlobeNewswire December 16, 2015

Catalyst Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 23, 2015

Beyond the Chart, What Price Data Reveals - Research on Endochoice Holdings, Catalyst Pharmaceuticals, Aquinox Pharmaceuticals and ARC Document Solutions

Accesswire November 19, 2015

Catalyst Pharmaceuticals Announces Third Quarter 2015 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2015

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Tuesday, November 10, 2015

GlobeNewswire November 4, 2015

Catalyst Pharmaceuticals Announces Poster Presentation at 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

GlobeNewswire October 27, 2015

Catalyst Pharmaceuticals to Present at 14th Annual BIO Investor Forum

GlobeNewswire October 19, 2015

Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for the Method of Treating Tourette's Disorder With GABA-Aminotransferase Inactivators

GlobeNewswire October 13, 2015

Catalyst Pharmaceuticals Announces a Clinical Trial for Pediatric Patients With Congenital Myasthenic Syndromes

GlobeNewswire October 6, 2015

Catalyst Pharmaceuticals Announces Intent to Develop a Generic Equivalent of Sabril

GlobeNewswire September 9, 2015

Catalyst Pharmaceuticals to Present at Rodman & Renshaw's 17th Annual Global Investment Conference

GlobeNewswire September 3, 2015

Catalyst Pharmaceuticals (Nasdaq: CPRX) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire August 18, 2015